B-intervention	0	11	Intravenous
I-intervention	12	23	pamidronate
O	24	30	versus
B-control	31	35	oral
I-control	36	39	and
I-control	40	51	intravenous
I-control	52	62	clodronate
O	63	65	in
B-condition	66	70	bone
I-condition	71	81	metastatic
O	82	88	breast
O	89	95	cancer
O	95	96	:
O	97	98	a
O	99	109	randomized
O	109	110	,
O	111	115	open
O	115	116	-
O	116	121	label
O	121	122	,
O	123	126	non
O	126	127	-
O	127	138	inferiority
O	139	144	Phase
O	145	148	III
O	149	154	trial
O	154	155	.

O	156	164	Patients
O	165	169	with
O	170	182	metastasized
O	183	189	breast
O	190	196	cancer
O	197	202	often
O	203	209	suffer
O	210	214	from
O	215	225	discomfort
O	226	232	caused
O	233	235	by
O	236	246	metastatic
O	247	251	bone
O	252	259	disease
O	259	260	.

O	261	265	Thus
O	265	266	,
O	267	282	osteoprotection
O	283	285	is
O	286	288	an
O	289	298	important
O	299	303	part
O	304	306	of
O	307	314	therapy
O	315	317	in
O	318	324	breast
O	325	331	cancer
O	332	344	metastasized
O	345	347	to
O	348	352	bone
O	352	353	,
O	354	357	and
O	358	373	bisphosphonates
O	374	375	(
O	375	378	BPs
O	378	379	)
O	380	383	are
O	384	385	a
O	386	391	major
O	392	403	therapeutic
O	404	410	option
O	410	411	.

O	412	414	In
O	415	419	this
O	420	425	study
O	425	426	,
O	427	430	our
O	431	441	objectives
O	442	446	were
O	447	449	to
O	450	457	compare
O	458	461	the
O	462	466	side
O	467	474	effects
O	475	477	of
O	478	482	oral
O	483	489	versus
O	490	501	intravenous
O	502	504	BP
O	505	514	treatment
O	515	518	and
O	519	521	to
O	522	528	assess
O	529	534	their
O	535	543	clinical
O	544	557	effectiveness
O	557	558	.

O	559	561	In
O	562	566	this
O	567	578	prospective
O	579	589	randomized
O	589	590	,
O	591	595	open
O	595	596	-
O	596	601	label
O	601	602	,
O	603	606	non
O	606	607	-
O	607	618	inferiority
O	619	624	trial
O	624	625	,
O	626	628	we
O	629	637	enrolled
O	638	644	breast
O	645	651	cancer
O	652	660	patients
O	661	665	with
O	666	668	at
O	669	674	least
O	675	678	one
O	679	683	bone
O	684	694	metastasis
O	695	698	and
O	699	701	an
O	702	709	Eastern
O	710	721	Cooperative
O	722	730	Oncology
O	731	736	Group
O	737	748	performance
O	749	755	status
O	756	758	of
O	759	760	0
O	760	761	-
O	761	762	2
O	762	763	.

O	764	772	Patients
O	773	777	were
O	778	786	randomly
O	787	795	assigned
O	796	798	to
O	799	802	one
O	803	805	of
O	806	809	the
O	810	815	three
O	816	825	treatment
O	826	832	groups
O	832	833	:
O	834	835	A
O	835	836	,
O	837	839	60
O	840	842	mg
O	843	854	pamidronate
O	855	868	intravenously
O	869	872	q3w
O	872	873	;
O	874	875	B
O	875	876	-
O	876	878	iv
O	878	879	,
O	880	883	900
O	884	886	mg
O	887	897	clodronate
O	898	911	intravenously
O	912	915	q3w
O	915	916	;
O	917	920	and
O	921	922	B
O	922	923	-
O	923	924	o
O	924	925	,
O	926	927	2
O	927	928	,
O	928	931	400
O	932	934	mg
O	935	939	oral
O	940	950	clodronate
O	951	956	daily
O	956	957	.

O	958	969	Assessments
O	970	974	were
O	975	984	performed
O	985	987	at
O	988	996	baseline
O	997	1000	and
O	1001	1006	every
O	1007	1008	3
O	1009	1015	months
O	1016	1026	thereafter
O	1026	1027	.

O	1028	1035	Between
O	1036	1040	1995
O	1041	1044	and
O	1045	1049	1999
O	1049	1050	,
B-total-participants	1051	1054	321
B-eligibility	1055	1063	patients
I-eligibility	1064	1068	with
I-eligibility	1069	1078	confirmed
I-eligibility	1079	1083	bone
I-eligibility	1084	1094	metastases
I-eligibility	1095	1099	from
I-eligibility	1100	1106	breast
I-eligibility	1107	1113	cancer
O	1114	1118	were
O	1119	1127	included
O	1128	1130	in
O	1131	1134	the
O	1135	1140	study
O	1140	1141	.

O	1142	1144	At
O	1145	1150	first
O	1151	1157	follow
O	1157	1158	-
O	1158	1160	up
O	1160	1161	,
B-outcome	1162	1178	gastrointestinal
I-outcome	1179	1180	(
I-outcome	1180	1182	GI
I-outcome	1182	1183	)
I-outcome	1184	1189	tract
I-outcome	1190	1194	side
I-outcome	1195	1202	effects
O	1203	1207	were
O	1208	1212	most
O	1213	1219	common
O	1219	1220	,
O	1221	1224	and
O	1225	1232	adverse
O	1233	1240	effects
O	1241	1243	on
O	1244	1247	the
O	1248	1250	GI
O	1251	1256	tract
O	1257	1261	were
O	1262	1266	more
O	1267	1275	frequent
O	1276	1278	in
O	1279	1282	the
O	1283	1287	oral
O	1288	1297	treatment
O	1298	1303	group
O	1304	1305	(
O	1305	1306	P
O	1306	1307	=
O	1307	1308	0
O	1308	1309	.
O	1309	1312	002
O	1313	1316	and
O	1317	1318	P
O	1318	1319	<
O	1319	1320	0
O	1320	1321	.
O	1321	1324	001
O	1324	1325	,
O	1326	1338	respectively
O	1338	1339	)
O	1339	1340	.

O	1341	1346	There
O	1347	1351	were
O	1352	1354	no
O	1355	1368	statistically
O	1369	1380	significant
O	1381	1392	differences
O	1393	1398	among
O	1399	1402	the
O	1403	1412	treatment
O	1413	1420	cohorts
O	1421	1424	for
O	1425	1430	other
B-outcome	1431	1441	documented
I-outcome	1442	1446	side
I-outcome	1447	1454	effects
I-outcome	1455	1456	(
I-outcome	1456	1460	skin
I-outcome	1460	1461	,
I-outcome	1462	1467	serum
I-outcome	1468	1480	electrolytes
I-outcome	1480	1481	,
I-outcome	1482	1489	urinary
I-outcome	1490	1495	tract
I-outcome	1495	1496	,
I-outcome	1497	1503	immune
I-outcome	1504	1510	system
I-outcome	1510	1511	,
I-outcome	1512	1515	and
I-outcome	1516	1522	others
I-outcome	1522	1523	)
O	1523	1524	.

O	1525	1527	No
O	1528	1539	significant
O	1540	1551	differences
O	1552	1554	in
B-outcome	1555	1563	clinical
I-outcome	1564	1577	effectiveness
I-outcome	1578	1580	of
I-outcome	1581	1583	BP
I-outcome	1584	1593	treatment
O	1593	1594	,
O	1595	1597	as
O	1598	1606	assessed
O	1607	1609	by
O	1610	1614	pain
O	1615	1620	score
O	1620	1621	,
O	1622	1626	were
O	1627	1635	detected
O	1636	1641	among
O	1642	1645	the
O	1646	1652	groups
O	1652	1653	;
O	1654	1661	however
O	1661	1662	,
B-outcome	1663	1673	pathologic
I-outcome	1674	1683	fractures
O	1684	1688	were
O	1689	1693	more
O	1694	1705	effectively
O	1706	1715	prevented
O	1716	1718	by
O	1719	1730	intravenous
O	1731	1735	than
O	1736	1740	oral
O	1741	1743	BP
O	1744	1758	administration
O	1759	1760	(
O	1760	1761	P
O	1761	1762	=
O	1762	1763	0
O	1763	1764	.
O	1764	1766	03
O	1766	1767	)
O	1767	1768	.

B-outcome	1769	1782	Noncompliance
I-outcome	1783	1788	rates
O	1789	1793	were
O	1794	1801	similar
O	1802	1807	among
O	1808	1811	the
O	1812	1817	study
O	1818	1825	cohorts
O	1825	1826	.

O	1827	1829	We
O	1830	1838	conclude
O	1839	1843	that
O	1844	1848	oral
O	1849	1851	BP
O	1852	1861	treatment
O	1862	1864	is
O	1865	1878	significantly
O	1879	1889	associated
O	1890	1894	with
O	1895	1901	higher
O	1902	1907	rates
O	1908	1910	of
O	1911	1918	adverse
O	1919	1921	GI
O	1922	1926	side
O	1927	1934	effects
O	1934	1935	.

O	1936	1948	Additionally
O	1948	1949	,
O	1950	1953	our
O	1954	1958	data
O	1959	1967	indicate
O	1968	1972	that
O	1973	1984	intravenous
O	1985	1987	BP
O	1988	2002	administration
O	2003	2005	is
O	2006	2010	more
O	2011	2020	effective
O	2021	2025	than
O	2026	2030	oral
O	2031	2040	treatment
O	2041	2043	in
O	2044	2054	prevention
O	2055	2057	of
O	2058	2068	pathologic
O	2069	2078	fractures
O	2078	2079	;
O	2080	2085	hence
O	2085	2086	,
O	2087	2091	oral
O	2092	2106	administration
O	2107	2113	should
O	2114	2116	be
O	2117	2127	considered
O	2128	2132	with
O	2133	2140	caution
O	2140	2141	.
